Compare D R Horton Inc (DHI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Merck & Co., Inc. — how do they compare? D R Horton Inc trades at $149.5 (market cap $42.53B), while Merck & Co., Inc. trades at $124 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 7× D R Horton Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| DHI | MRK | |
|---|---|---|
Market Cap | $42.53B | $298.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $129.52 |
52-Week Low | $129.82 | $77.60 |
Enterprise Value | $47.25B | $341.72B |
Dividend Yield | 1.2% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $148.85, down 1.8% over 24 hours, with a bearish technical signal from moving averages but oversold RSI levels. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025, with revenue declining to $34.25 billion in 2025. Analyst consensus is split between Buy and Hold ratings, with a $164.71 price target suggesting potential upside. Recent news highlights housing market headwinds from rising mortgage rates but also potential support from new legislation.
DHI presents a cautious opportunity with attractive valuation multiples (P/E 13.98, P/S 1.32) and a stable dividend, but faces risks from housing affordability pressures and volatile cash flows. Investors should weigh the company's scale and market position against macroeconomic challenges in the homebuilding sector.
Merck (MRK) trades at $124.03, up 0.4% today, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 67.57% analyst buy rating support momentum. The company's acquisition of Terns Pharmaceuticals, announced on April 7, 2026, aims to bolster its oncology pipeline, while a dividend of $0.85 per share is scheduled for July 2026.
Outlook remains positive with a consensus price target of $137.30, though risks include rising debt levels and competitive pressures. Revenue growth is steady, but net income is projected to decline in 2026, highlighting execution challenges amid strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
